Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. (Q36610990)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

review article

1 reference

title

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ronit Simantov

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Scott Wilhelm

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Christopher Carter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Mark Lynch

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Timothy Lowinger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Jacques Dumas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Roger A Smith

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Susan Kelley

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

835-844

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrd2130

20 December 2019

exact match

0 references

cites work

Mechanism of activation of a human oncogene

1 reference

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

31 March 2020

1 reference

31 March 2020

Tumor suppressor genes

1 reference

31 March 2020

1 reference

Uninfected avian cells contain RNA related to the transforming gene of avian sarcoma viruses

31 March 2020

1 reference

Cellular oncogenes and retroviruses

31 March 2020

1 reference

On a possible epigenetic mechanism(s) of tumor cell heterogeneity. The role of DNA methylation

31 March 2020

1 reference

The molecular basis of oncogenes and tumor suppressor genes.

31 March 2020

1 reference

Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor

31 March 2020

1 reference

Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus

31 March 2020

1 reference

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

31 March 2020

1 reference

Epidermal growth factor and its receptor

31 March 2020

1 reference

c-Src and cooperating partners in human cancer

31 March 2020

1 reference

Cancer therapeutics: targeting the dark side of Myc.

31 March 2020

1 reference

The Fos family of transcription factors and their role in tumourigenesis

31 March 2020

1 reference

The role of Raf kinases in malignant transformation.

31 March 2020

1 reference

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

31 March 2020

1 reference

Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma

31 March 2020

1 reference

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

31 March 2020

1 reference

Targeting RAS signalling pathways in cancer therapy

31 March 2020

1 reference

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

31 March 2020

1 reference

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

31 March 2020

1 reference

Raf-1 expression may influence progression to androgen insensitive prostate cancer

31 March 2020

1 reference

RAF antisense oligonucleotide as a tumor radiosensitizer

31 March 2020

1 reference

Discovery of a novel Raf kinase inhibitor

31 March 2020

1 reference

A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors

31 March 2020

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

31 March 2020

Erlotinib hydrochloride

1 reference

Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases

31 March 2020

1 reference

Finding the needle in the haystack: why high-throughput screening is good for your health

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach

31 March 2020

1 reference

Design and discovery of small molecules targeting raf-1 kinase

31 March 2020

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

BAY 43-9006 inhibition of oncogenic RET mutants

31 March 2020

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

31 March 2020

1 reference

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

31 March 2020

1 reference

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

31 March 2020

1 reference

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

31 March 2020

1 reference

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

31 March 2020

1 reference

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

31 March 2020

1 reference

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

31 March 2020

1 reference

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

31 March 2020

1 reference

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

31 March 2020

1 reference

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

31 March 2020

1 reference

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer

31 March 2020

1 reference

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

31 March 2020

1 reference

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

31 March 2020

1 reference

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

31 March 2020

1 reference

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

31 March 2020

1 reference

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

31 March 2020

1 reference

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

31 March 2020

1 reference

High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma

31 March 2020

1 reference

FLT-3: a new focus in the understanding of acute leukemia

31 March 2020

1 reference

Imatinib resistance in gastrointestinal stromal tumors.

31 March 2020

1 reference

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer

31 March 2020

1 reference

BRAF is a therapeutic target in aggressive thyroid carcinoma.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17016424%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference